iPSC Genome Editing Rapid Automated Cell Line Editing (RACE™)

With extensive experience in genome editing and induced pluripotent stem cell (iPSC) technologies, custom services are offered to support preclinical stage autologous, allogeneic, and genomic projects. These services cover a broad range of needs, from generating preclinical proof-of-concept cell lines and animal models to developing specialized assays tailored to specific research goals. The expertise extends to conducting potency, efficacy, and safety assessments, ensuring that therapeutic candidates meet rigorous standards throughout the development process.

Additionally, guidance is provided on chemistry, manufacturing, and controls (CMC) aspects, including consultation for vector design and cell line manufacturing to support scalable production. By integrating cutting-edge technology platforms, this service streamlines the screening and evaluation of therapeutic candidates, helping to overcome key hurdles on the path to clinical development. The ultimate goal is to facilitate efficient and effective progression through preclinical stages, accelerating the timeline toward Investigational New Drug (IND) application filing.

This comprehensive approach combines innovation in genetic engineering with practical expertise in preclinical research and manufacturing, enabling researchers to advance their projects with confidence and readiness for regulatory requirements.